Archives des études
Toutes les études
Page 10 sur 45 · 1080 études
40/100
23Buffett
Pan American Silver: Juanicipio Upgrades the Silver Book, But $44 Already Pays for the Transition
Pan American Silver is an Americas-focused, silver-first precious-metals miner whose September 2025 MAG acquisition added a 44% stake in the high-grade Juanicipio mine, lifting 2026 guidance to 25-27 Moz silver and 700-750 koz gold on a net-cash balance sheet. The portfolio is genuinely better than the 2022 trough, but at $44.39 the stock trades near 9.2x EV/EBITDA on a 7% free-cash-flow yield, already pricing the upgrade while Escobal and Navidad stay politically frozen and 2026 cost guidance leans on $70 silver against roughly $58 spot. Rating Hold: a better silver miner with no clear margin of safety, where a buy needs either the mid-$20s or proof that normalized free cash flow holds closer to the base case than the conservative one.
45/100
RemeGen: Two Self-Developed Drug Franchises and an Export Licensing Engine, With the A-Share Already Pricing a Cleaner Future Than the Filings Justify
RemeGen is a commercializing China innovative-biopharma with two self-developed franchises — telitacicept in autoimmune disease and disitamab vedotin in ADC oncology — plus an ex-China licensing engine (Vor Bio, Santen, AbbVie) that has become part of the business model. 2025 product sales reached CNY 2.31bn (up 35.8%) and reported profit turned positive at CNY 709.7m, but operating cash flow was only CNY 52.3m (about 0.07x conversion), Q1 2026 profit after non-recurring items stayed negative, and the A-share trades at roughly a 96.5% premium to the H-share — above even the optimistic per-share value. Rating Avoid: a good company at the wrong price on the Shanghai line, where an entry needs both a lower A-share price (CNY 36-40) and proof that recurring earnings quality has caught up to the approvals.
44/100
46Buffett
Zhejiang Shuanghuan Driveline: A Precision-Gear Cash Engine Carrying a Still-Optional Robot-Reducer Bet
Zhejiang Shuanghuan Driveline is a precision-gear specialist whose profit still comes from automotive transmission and e-drive gears, with robot RV reducers (housed in 61.29%-owned Huandong, now seeking a STAR Market listing) as a still-speculative second engine. Four straight years of rising revenue (CNY 9.11bn in 2025) and attributable profit (CNY 1.262bn), with operating cash flow above net income every year, make the transition credible, yet Q1 2026 recurring profit fell 4.04% and the loudest humanoid-customer claims stay unverified in primary filings. Rating Hold: the auto-gear cash engine is real and the reducer option is credible, but at CNY 39.42 the price already capitalizes much of that optionality, leaving no obvious margin of safety.
47/100
Kelun-Biotech: A Commercializing China ADC Franchise Priced for Much of Its sac-TMT and MSD Global Success
Kelun-Biotech is a commercial-stage China ADC developer whose equity value is dominated by its sac-TMT (TROP2) franchise in Greater China plus ex-China royalty economics from MSD. In 2025 product sales inflected to RMB542.7m within RMB2.06bn total revenue and the balance sheet held RMB4.56bn cash with no borrowings, yet the company still posted a RMB382.0m net loss as nearly all equity value concentrates in one molecule. Rating Hold: a real ADC franchise is forming, but at HK$419 the stock already prices in much of the sac-TMT China plus MSD global success path and offers no margin of safety.
36/100
39Buffett
Gold Fields: A De-Rated but Reshaped Global Gold Miner Still Priced for Execution and Country Risk
Gold Fields is a globally diversified gold miner running eight operating mines across South Africa, Ghana, Chile, Peru and Australia plus the Windfall project in Canada, reshaped around the new Salares Norte flagship and the Osisko and Gold Road acquisitions. 2025 delivered a realized gold price of US$3,496/oz, production of 2.438Moz and adjusted free cash flow of US$2.97 billion, yet the US ADR has de-rated quickly from US$38.60 to US$31.88 in a broad gold selloff rather than on any company-specific break. Rating Cautious Buy: an improved but still-cyclical portfolio trading at a discount to peers, where Salares Norte execution and Ghana Tarkwa fiscal terms keep a full-quality rerating away and the ideal buy sits at US$26 to US$29, below the current price.
36/100
26Buffett
AngloGold Ashanti: A Re-Rated Major Gold Miner in Transition, Cash-Rich but Reserve-Light and Priced Near Fair Value
AngloGold Ashanti is a globally diversified major gold miner producing 3.1Moz a year across roughly ten mines, reshaped by the 2024 Centamin/Sukari acquisition and a 2023 redomicile to a UK plc with a primary NYSE listing. 2025 delivered record free cash flow of US$2.9 billion and a year-end adjusted net cash position, but the shares have already re-rated about 69% in a year and a 21.91Moz reserve base implies only about seven years of reserve life against 3.1Moz of annual output. Rating Hold: a much-improved cyclical cash generator now trading near fair value at roughly 0.85x P/NAV, where the easy rerating money has been made and further upside hinges on reserve replacement (Nevada's Arthur) and a gold tape staying generous.
38/100
41Buffett
Barrick Mining: A World-Class Gold-and-Copper Portfolio in Transition, Discounted for Complexity and Priced Near Fair Value
Barrick Mining is a senior gold-and-copper miner with world-class reserve depth (85Moz gold, 18Mt copper), district quality in Nevada and Pueblo Viejo, and a balance sheet strong enough to fund both record shareholder returns and future growth. Record 2025 cash flow (US$7.69 billion operating, US$3.87 billion free) proved the operating leverage, but the stock trades at a persistent discount to peers because sovereign risk in Mali, a Reko Diq budget review, a Newmont dispute over Nevada, and an unfinished North American carve-out all cloud the path from ore to shareholder value. Rating Hold: the gold cash flows and copper optionality are real, but the price already reflects strong metals and leaves only a moderate cushion against execution risk, with a defensible entry only below roughly US$26.
44/100
28Buffett
OR Royalties: A Mid-Tier Royalty Franchise Re-Rating With Visible Growth, Priced Around Fair Value
OR Royalties is a mid-tier precious-metals royalty and streaming company anchored by a 3-5% NSR on the Tier-1 Canadian Malartic mine, with 196 interests and 23 producing assets. 2025 revenue jumped 45% to US$277.4 million on a soaring realized gold price and the company finished the year debt-free, while the 2030 outlook of 120,000-135,000 GEOs is backed by named projects rather than blue-sky exploration; yet much of the earnings step-up is gold-price torque and Canadian Malartic still dominates the story. Rating Hold: a genuinely improving franchise re-rating with visible growth, but priced around fair value, with a defensible entry only in the low-to-mid US$20s, below the conservative fair value of US$28.
41/100
68Buffett
Chow Tai Fook Jewellery Group: A Scale Leader in Transition, Priced Around Fair Value
Chow Tai Fook is the scale leader in Greater China branded jewellery, with a mostly franchised mainland network and a profit mix tilting toward higher-margin fixed-price gold products. FY2026 revenue rose 5.3% to HK$94.4 billion while operating profit jumped 27.8% to HK$18.85 billion on richer mix and store rationalisation, yet at HK$11.83 the shares sit around the base-case fair value of HK$12.2 with zero margin of safety and an unresolved debate over margin durability. Rating Hold: a cash-generative, scale-leading franchise re-rating on mix and discipline, but priced around fair value, with a defensible entry only below the conservative fair value of HK$9.8.
U.S. Market Close Daily | 2026-06-24
U.S. equities finished mixed in a sector-rotation tape as semiconductor weakness capped the S&P 500 and Nasdaq while lower oil and yields supported broader breadth.
41/100
THK: A Category-Defining Linear-Motion Franchise Re-Rated on Restructuring and a Still-Unbooked Robotics Option
THK is the Japanese precision-component maker that commercialized the world's first LM Guide and still leads in linear-motion hardware (LM guides, ball screws, actuators) sold into machine tools, electronics, and factory automation. After exiting a low-return automotive business and adopting an ROE-above-10% policy, continuing-operations earnings are recovering toward 2026 guidance of revenue around 276 billion yen and operating income around 31 billion yen, yet at 7,802 yen the stock trades near 38.5x forward EPS and 3.3x book, pricing in both the restructuring and a robotics optionality the filings do not yet quantify. Rating Hold: a real industrial franchise whose stock has run ahead of delivered execution, with an ideal buy zone of 3,900 to 4,100 yen.
43/100
Nabtesco: A Scarce Robot-Reducer Franchise Carrying a Growth Premium on a Still-Cyclical Base
Nabtesco is a diversified Japanese precision-machinery group whose profit engine is industrial-robot RV reducers, where it holds about 60% of the global market for medium- to large-joint reducers, backed by transport, aircraft, marine, and door-system businesses. FY2025 continuing-operations sales rose 9.8% and operating income 60.3%, yet at JPY 5,707 the stock trades near record highs at roughly 36x FY2026 EPS and 43x FY2025 EPS, pricing in both the cyclical recovery and a large slice of still-unproven humanoid optionality. Rating Watch: a genuine franchise on a capital-heavy cyclical base, with no margin of safety until the mid-3,000s.
44/100
Shenzhen Zhaowei: A Real Precision Micro-Drive Business Undergoing a Thematic Robot Re-Rating
Zhaowei is a 25-year-old precision micro-drive systems supplier whose 2025 revenue was RMB1.72 billion, with automotive the real engine at 64.5% of sales while the headline-grabbing embodied-robotics line was just 1.39%. The A-share trades at about 91.5x trailing earnings and the H-share implies a roughly 46.6% discount, so the market is pre-paying for a humanoid-supply-chain future that the filings have not yet delivered. Rating Hold: a credible micro-drive platform with real robot optionality, but the A-share still prices too much of that optionality in advance; the ideal buy zone is CN¥44-61.
50/100
Akeso, Inc.: A Commercial-Stage Antibody Innovator Still Priced on Ivonescimab's Global Option Value
Akeso is a commercial-stage Chinese antibody innovator with seven marketed products and record 2025 commercial sales of RMB3.03 billion, anchored by cadonilimab and ivonescimab. Yet the stock trades as a referendum on one molecule: whether ivonescimab's strong China data (a HARMONi-6 overall-survival win, HR 0.66) can survive global regulators, while 2025 operating cash flow stayed negative at RMB947.6 million and the shares fetch about 22x trailing sales. Rating Hold: rare science and a real China franchise, but the price still pre-pays too much of ivonescimab's ex-China upside; the ideal buy zone is HK$58-64.
49/100
XtalPi Holdings: An AI-for-Science Platform Climbing from Fee-for-Service Work to Milestone Economics, Still Priced Ahead of Proof
XtalPi is a founder-led AI-for-science platform built by MIT-trained physicists, selling drug-discovery and R&D-automation solutions as it tries to climb from fee-for-service work toward milestone-and-royalty economics. 2025 revenue jumped 201.2% to RMB802.6 million as drug-discovery solutions rose to RMB537.9 million from RMB103.7 million, but one customer was over 45% of sales, reported profit leaned on RMB514.0 million of fair-value gains, and operating cash flow stayed negative at RMB-165.4 million. Rating Hold: serious science with blue-chip partners (DoveTree, Lilly, Pfizer) and a large cash cushion, yet the price still pays for cleaner, broader earnings than the platform has delivered; the ideal buy zone is HK$3.8-4.1.
51/100
Asymchem Laboratories: A Proven Small-Molecule CDMO in Transition to New Modalities, Already Priced for Success
Asymchem is a founder-led Chinese CDMO anchored in commercial small-molecule process chemistry, with emerging peptide, oligonucleotide and biologics work now about 30% of revenue. 2025 revenue rose 14.9% to RMB 6.67bn with adjusted net profit of RMB 1.25bn, order backlog reached US$1.385bn (+31.65%), and Q1 2026 emerging-business revenue jumped 74.1% — yet the A-share trades near 40x trailing earnings (about a 2.4% owner-earnings yield), while founder-concentrated governance and the BIOSECURE policy overhang cap the multiple. Rating Hold: a high-quality chemistry franchise whose new-modality transition is real, but the current price already pays for most of the 2026 recovery; the ideal buy zone is CNY 68-70.
U.S. Market Close Daily | 2026-06-23
U.S. equities logged a rotation-led pullback as AI and semiconductor selling hit the Nasdaq while defensives and lower Treasury yields cushioned broader stress.
43/100
24Buffett
Energy Transfer LP: A Discounted Midstream Cash Cow Turning Its Asset Empire Into Disciplined Gas-Led Growth
Energy Transfer is a roughly $66bn K-1 master limited partnership that owns about 140,000 miles of integrated U.S. gas, NGL, crude and export infrastructure across 44 states, throwing off $8.20bn of distributable cash flow to partners against a $4.56bn payout, or about 1.8x coverage. Its 2026 EBITDA guidance has been raised twice to $18.2bn-$18.6bn as a gas-and-NGL project backlog converts to cash, yet a 2020 distribution cut, MLP governance frictions and heavy reinvestment keep the units on a roughly 7.1% yield and a persistent structure discount. Rating Hold: integrated bottlenecks support a safe payout and organic reacceleration, but the discount closes only partly until disciplined execution is proven through repetition rather than another deal.
42/100
89Buffett
Graco Inc.: A Premium Fluid-Handling Compounder Priced for a Recovery Not Yet Visible
Graco is a century-old, distributor-led fluid-handling equipment maker with premium-industrial economics — high-20s operating margins, ~23% ROIC, and ~40% of revenue from parts and accessories. But organic sales fell 6% in Q1 2026 and reported growth now leans on bolt-on M&A (Valco Melton at ~14x EBITDA), while the stock trades near 24.8x earnings with no margin of safety. Rating Hold: a good company at an ordinary price, already priced for a cleaner recovery than the evidence yet shows.
42/100
MKS Inc.: A Hybrid Process-Control Platform Priced for a Near-Best-Case AI Cycle
MKS is a picks-and-shovels supplier of vacuum, photonics, and materials and chemistry technologies to semiconductor and advanced-packaging manufacturing, reshaped by the 2022 Atotech deal into a hybrid that is part cyclical subsystem vendor and part recurring-chemistry platform. Full-year 2025 revenue reached US$3.93 billion with semiconductor and electronics-and-packaging both growing double digits, and the February 2026 refinancing eased the post-Atotech debt strain, yet at about US$406 the stock trades near 34x trailing EBITDA and 52x non-GAAP earnings. Rating Avoid: a genuinely better business than two years ago, but the price already discounts a near-best-case AI and packaging cycle, with a margin of safety only opening below roughly US$180.
44/100
Renesas: A Cyclical Embedded Compounder Priced for a Transition Still Unproven
Renesas is a cyclical embedded-semiconductor compounder centered on automotive MCUs, with analog, power, and connectivity layers and a new system-design software push after Altium. Q1 2026 non-GAAP revenue rose 20.6% to JPY 372.3 billion at a 59.2% gross margin, and 2025 free cash flow reached JPY 328.2 billion, yet IFRS profit swung to a loss on Wolfspeed-related impairments. Rating Hold: a real franchise with better cash than the headlines, but at JPY 4,734 the price already discounts much of the recovery, with a wider margin of safety only opening in the JPY 3,500-3,800 range.
40/100
59Buffett
Inventec: An AI-Server Manufacturer Still Earning Assembly Margins
Inventec is a Taiwan ODM/EMS maker that has shifted from a notebook-led business to a server-led one, with servers above half of sales on the AI build-out. Q1 2026 revenue rose 28% to NT$200.3 billion, yet gross margin slipped to 5.1% and operating cash flow has converted only about 0.8x of net income over 2021-2025, so AI growth is still monetized through thin, working-capital-heavy assembly economics. Rating Hold: a better business than its old notebook-ODM image, but at NT$67.7 the stock already prices in much of the transition, with a wide margin of safety only opening in the low-to-mid NT$40s.
48/100
Leaderdrive: China's Harmonic-Reducer Leader Priced for a Humanoid Future
Leaderdrive is China's domestic leader in harmonic-drive (strain-wave) reducers, the precision part inside robot joints, now extending from stand-alone components into mechatronic actuators. 2025 revenue jumped 47.3% to RMB 570.7 million with harmonic-reducer unit sales up 72.5%, yet at RMB 381.60 the stock trades near 123x sales and roughly 562x trailing earnings, pre-spending a humanoid-scale future that filings have not yet disclosed. Rating Avoid: a genuinely improving component leader at a speculative price, with every valuation scenario implying a loss from today's level until the humanoid ramp is proven or the price resets.
50/100
70Buffett
Auras Technology: A Thermal Vendor Climbing the AI Liquid-Cooling Stack
Auras is a Taiwanese thermal-management vendor shifting from legacy air cooling to higher-value AI-server liquid cooling, with 2025 revenue up 47.6% to TWD 23.28 billion. The mix shift is real (2026 Q1 liquid-cooling revenue passed 55% and gross margin reached 29.7%), but 2025 operating cash flow turned negative and the stock near 30.6x trailing earnings already discounts much of the 2026-2027 ramp. Rating Hold: genuine liquid-cooling share gains are visible, yet a wide margin of safety only opens below roughly TWD 690.